الإحصائيات الأساسية
| LEI | 549300UFONE2USNRQ615 |
| CIK | 1739426 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Osmotica Pharmaceuticals Plc
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2024 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| December 20, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| November 28, 2023 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* RVL Pharmaceuticals plc (Name of Issuer) Ordinary Shares, nominal value $0.01 per share (Title of Class of Securities) G6S41R101 (CUSIP Number) Andrew C. Hyman, Esq. c/o Athyrium Capital Management, LP 505 Fifth Avenue, Floor 18 New York, New Yo |
|
| November 27, 2023 |
Exhibit 2.1 RLF1 30177586v.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE ) In re: ) Chapter 11 ) REVITALID PHARMACEUTICAL CORP., et al., ) ) Case No. 23-11704 (BLS) Debtors.1 ) (Jointly Administered) ) ) Re: Docket Nos. 16 & 90 FINDINGS OF FACT, CONCLUSIONS OF LAW, AND ORDER (I) APPROVING THE DEBTORS’ (A) DISCLOSURE STATEMENT PURSUANT TO SECTIONS 1125 AND 1126(b) OF THE BANK |
|
| November 27, 2023 |
Exhibit 99.2 867)RUP 025 81,7('67$7(6%$1.5837&<&2857 ',675,&72) '(/$:$5( ,Q5H 59/3+$50$&(87,&$/6 ,1& 'HEWRU V &DVH1R /HDG&DVH1R -RLQWO\$GPLQLVWHUHG 0RQWKO\2SHUDWLQJ5HSRUW &KDSWHU 5HSRUWLQJ3HULRG(QGHG 3HWLWLRQ'DWH 0RQWKV3HQGLQJ ,QGXVWU\&ODVVLILFDWLRQ 5HSRUWLQJ0HWKRG $FFUXDO%DVLV &DVK%DVLV 'HEWRU V)XOO 7LPH(PSOR\HHV FXUUHQW 'HEWRU V)XOO 7LPH(PSOR\HHV DVRIGDWHRIRUGHUIRUUHOLHI 6XSSRUWLQJ'RFXPHQWDWLRQ |
|
| November 27, 2023 |
Exhibit 99.3 867 )RUP 025 81,7(' 67$7(6 %$1.5837&< &2857 ',675,&7 2) '(/$:$5( ,Q 5H 59/ 3+$50$&< //& 'HEWRU V &DVH 1R /HDG &DVH 1R -RLQWO\ $GPLQLVWHUHG 0RQWKO\ 2SHUDWLQJ 5HSRUW &KDSWHU 5HSRUWLQJ 3HULRG (QGHG 3HWLWLRQ 'DWH 0RQWKV 3HQGLQJ ,QGXVWU\ &ODVVLILFDWLRQ 5HSRUWLQJ 0HWKRG $FFUXDO %DVLV &DVK %DVLV 'HEWRU V )XOO 7LPH (PSOR\HHV FXUUHQW 'HEWRU V )XOO 7LPH (PSOR\HHV DV RI GDWH RI RUGHU IRU UHOLHI |
|
| November 27, 2023 |
Exhibit 99.1 867 )RUP 81,7(' 67$7(6 %$1.5837&< &2857 ',675,&7 2) '(/$:$5( ,Q 5H 5(9,7$/,' 3+$50$&(87,&$/ &253 'HEWRU V &DVH 1R /HDG &DVH 1R -RLQWO\ $GPLQLVWHUHG 0RQWKO\ 2SHUDWLQJ 5HSRUW &KDSWHU 5HSRUWLQJ 3HULRG (QGHG 3HWLWLRQ 'DWH 0RQWKV 3HQGLQJ ,QGXVWU\ &ODVVLILFDWLRQ 5HSRUWLQJ 0HWKRG $FFUXDO %DVLV &DVK %DVLV 'HEWRU V )XOO 7LPH (PSOR\HHV FXUUHQW 'HEWRU V )XOO 7LPH (PSOR\HHV DV RI GDWH RI RUGHU IR |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| November 1, 2023 |
OSMT / Osmotica Pharmaceuticals Plc / Altchem Ltd - SC 13D/A (AMENDMENT NO. 2) Activist Investment SC 13D/A 1 sc13da110123.htm SC 13D/A (AMENDMENT NO. 2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) RVL Pharmaceuticals plc (formerly known as Osmotica Pharmaceuticals plc) (Name of Issuer) Ordinary shares, nominal value $0.01 per share (Title of Class of Securities) G6S41R101 (CUSIP Number) David C |
|
| October 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| October 20, 2023 |
Exhibit 10.1 Execution Version SENIOR SECURED SUPERPRIORITY DEBTOR-IN-POSSESSION TERM LOAN CREDIT AGREEMENT Dated as of October 16, 2023 among REVITALID PHARMACEUTICAL CORP., as the Borrower, CERTAIN SUBSIDIARIES OF THE BORROWER, as the Guarantors, ATHYRIUM OPPORTUNITIES IV ACQUISITION LP, as the Administrative Agent and Collateral Agent and THE LENDERS PARTY HERETO TABLE OF CONTENTS Page Article |
|
| October 13, 2023 |
Exhibit 10.1 SETTLEMENT TERM SHEET This binding term sheet (the “Term Sheet”), dated as of October 4, 2023 sets forth the terms of a compromise and settlement by and among (i) RVL Pharmaceuticals, Inc. (f/k/a, RevitaLid, Inc.) (“RVL”) and its subsidiaries and affiliates, including the Buyer (as defined below) (collectively, with RVL, the “Company”) and (ii) the undersigned “Sellers” under the SPA |
|
| October 13, 2023 |
IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE Exhibit 99.1 Solicitation Version IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: RevitaLid Pharmaceutical Corp., et al.,1 Debtors. ) ) ) ) ) ) ) Chapter 11 Case No. [●] (Joint Administration Requested) Joint PREPACKAGED Chapter 11 Plan OF REvitalid pharmaceutical corp. AND ITS SUBSIDIARIES THIS CHAPTER 11 PLAN IS NOT AN OFFER WITH RESPECT TO ANY SECURITIES OR A SOLICITAT |
|
| October 13, 2023 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* RVL Pharmaceuticals plc (Name of Issuer) Ordinary Shares, nominal value $0.01 per share (Title of Class of Securities) G6S41R101 (CUSIP Number) Andrew C. Hyman, Esq. c/o Athyrium Capital Management, LP 505 Fifth Avenue, Floor 18 New York, New Yo |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Comm |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Comm |
|
| September 5, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| September 5, 2023 |
SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* RVL Pharmaceuticals plc (Name of Issuer) Ordinary Shares, nominal value $0.01 per share (Title of Class of Securities) G6S41R101 (CUSIP Number) Andrew C. Hyman, Esq. c/o Athyrium Capital Management, LP 505 Fifth Avenue, Floor 18 New York, New York |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| August 25, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| August 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2023 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| August 25, 2023 |
RVL PHARMACEUTICALS PLC 400 Crossing Boulevard Bridgewater, New Jersey 08807 RVL PHARMACEUTICALS PLC 400 Crossing Boulevard Bridgewater, New Jersey 08807 August 25, 2023 VIA EDGAR U. |
|
| August 23, 2023 |
As filed with the Securities and Exchange Commission on August 23, 2023. As filed with the Securities and Exchange Commission on August 23, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RVL PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) Ireland Not Applicable (State or other jurisdiction of incorporation or organization) (I. |
|
| August 23, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) RVL Pharmaceuticals plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Ordinary Shares, $0. |
|
| August 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| August 18, 2023 |
PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT RVL Pharmaceuticals plc Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 18, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 15, 2023, between RVL Pharmaceuticals plc, an Irish incorporated public limited company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to t |
|
| August 18, 2023 |
SERIES A-1 ORDINARY SHARE PURCHASE WARRANT RVL Pharmaceuticals plc Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 18, 2023 |
SERIES A-2 ORDINARY SHARE PURCHASE WARRANT RVL Pharmaceuticals plc Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 18, 2023 |
Exhibit 99.1 RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules August 16, 2023 at 8:00 AM EDT BRIDGEWATER, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) - RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution |
|
| August 18, 2023 |
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT RVL Pharmaceuticals plc Exhibit 4.1 PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT RVL Pharmaceuticals plc Warrant Shares: Initial Exercise Date: , 2023 THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditi |
|
| August 17, 2023 |
CUSIP No. G6S41R101 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 5)* RVL Pharmaceuticals plc (Name of Issuer) Ordinary Shares, nominal value $0.01 per share (Title of Class of Securities) G6S41R101 (CUSIP Number) Ben Silbert, Esq. 65 East 55th Street, 18th Floor New York, NY 10022 (212) 593-6900 (Name, |
|
| August 17, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-269440 PROSPECTUS SUPPLEMENT (To Prospectus dated February 6, 2023) 11,000,000 Ordinary Shares Pre-Funded Warrants to purchase up to 870,846 Ordinary Shares Up to 870,846 Ordinary Shares Underlying the Pre-Funded Warrants We are offering (i) 11,000,000 of our ordinary shares and (ii) 870,846 pre-funded warrants (“pre-funded warrants”) to purcha |
|
| August 14, 2023 |
Exhibit 10.1 Execution Version THIRD AMENDMENT TO NOTE PURCHASE AGREEMENT THIS THIRD AMENDMENT TO NOTE PURCHASE AGREEMENT (this “Agreement”) dated as of August 13, 2023 (the “Third Amendment Effective Date”) is entered into by and among REVITALID PHARMACEUTICAL CORP. (f/k/a OSMOTICA PHARMACEUTICAL CORP.), a Delaware corporation (the “Issuer”), the Guarantors party hereto, the Purchasers party here |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38709 RVL |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| August 14, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business Review - UPNEEQ® remains a significant potential value driver given its rapid early acceptance by providers, large total addressable market and untapped consumer opportunity - - Executed financing amendment with Athyrium, which, subject to certain conditio |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commissio |
|
| July 27, 2023 |
July 27, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commissio |
|
| June 2, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2023 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commission |
|
| May 25, 2023 |
May 25, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38709 RVL |
|
| May 11, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE RVL Pharmaceuticals plc Reports First Quarter 2023 Financial Results; Provides Commercial Update - First quarter 2023 UPNEEQ® net product sales grew 49%, or $2.9 million, over the prior year period to $8.8 million - - Enhanced operating leverage with a 32%, or $7.9 million, reduction in first quarter 2023 total operating expenditures from the prior year - - Major |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commission |
|
| April 24, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 12, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38709 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland Not Applicable (State or other jurisdiction of (I. |
|
| March 20, 2023 |
Subsidiaries of RVL Pharmaceuticals plc Exhibit 21.1 RVL Pharmaceuticals plc Subsidiary State or Other Jurisdiction of Organization RVL Holdings US LLC Delaware Osmotica Kereskedelmi es Szolgaltato Kft Hungary RVL Finance Limited Bermuda Osmotica Pharmaceutical Corp. Delaware RVL Pharmaceuticals, Inc. Delaware Osmotica Argentina, S.A. Argentina Valkyrie Group Holdings, Inc. Delaware RVL Pharmacy, LLC Delaware |
|
| March 20, 2023 |
Pharmaceutical Corp., the Guarantors party thereto, the Purchasers party thereto and Athyrium Exhibit 10.26 SECOND AMENDMENT TO NOTE PURCHASE AGREEMENT THIS SECOND AMENDMENT TO NOTE PURCHASE AGREEMENT (this “Agreement”) dated as of March 8 2023 (the “Second Amendment Effective Date”) is entered into by and among REVITALID PHARMACEUTICAL CORP. (f/k/a OSMOTICA PHARMACEUTICAL CORP.), a Delaware corporation (the “Issuer”), the Guarantors party hereto, the Purchasers party hereto and ATHYRIUM O |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2023 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| March 20, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Commercial Update - RVLP records exceptional year-over-year growth with UPNEEQ® launch into the medical aesthetics market - - Full year 2022 total revenues of $49.7 million, an increase of $32.2 million, or 184%, over 2021 - - Full year 2022 UPNEEQ net product sales of $ |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| February 2, 2023 |
RVL PHARMACEUTICALS PLC 400 Crossing Boulevard Bridgewater, New Jersey 08807 CORRESP 1 filename1.htm RVL PHARMACEUTICALS PLC 400 Crossing Boulevard Bridgewater, New Jersey 08807 February 2, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: RVL Pharmaceuticals plc Registration Statement on Form S-3 (File No. 333-269440) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under |
|
| January 30, 2023 |
EX-1 2 tm234881d1ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing on behalf of each of them of the Statement on Schedule 13D with respect to the ordinary shares, $0.01 nominal value per share, of RVL Pharmaceuticals plc and any further amendments to such statement on Schedule 13D executed by each of them pursuant to and in accordance with the prov |
|
| January 30, 2023 |
SC 13D/A 1 tm234881d1sc13da.htm SC 13D/A CUSIP No. G6S41R101 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 4)* RVL Pharmaceuticals plc (Name of Issuer) Ordinary Shares, nominal value $0.01 per share (Title of Class of Securities) G6S41R101 (CUSIP Number) Ben Silbert, Esq. 65 East 55th Street, 18th Floor |
|
| January 27, 2023 |
Exhibit 4.8 RVL PHARMACEUTICALS PLC And [ ] as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 Definitions 1 1.2 Other Definitions 5 1.3 Incorporation by Reference of Trust Indenture Act 5 1.4 Rules of Construction Unless the context otherwise requires: 6 ARTICLE 2 THE SECURITIES 6 2.1 Issuable in Series 6 2.2 Establishment of Terms of S |
|
| January 27, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) RVL Pharmaceuticals plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary Shares, $0. |
|
| January 27, 2023 |
As filed with the Securities and Exchange Commission on January 27, 2023. As filed with the Securities and Exchange Commission on January 27, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation or organization) Not Applicable (I |
|
| January 9, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE RVL Pharmaceuticals plc Announces Preliminary Fourth Quarter Sequential Growth of 21% and Full Year 2022 UPNEEQ® Net Product Sales - Expects fourth quarter 2022 preliminary UPNEEQ net product sales of approximately $12.1 million, representing an increase of 21% over the third quarter 2022, and approximately $36.5 million for full year 2022 - - Approximately 4,300 |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 10, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE RVL Pharmaceuticals plc Reports Third Quarter 2022 Financial Results; Provides Commercial Update - Third quarter 2022 UPNEEQ? net product sales of $10.0 million; 19% above second quarter 2022; 355% above third quarter 2021 - - Approximately 3,500 cumulative unique medical aesthetics practices placed orders for UPNEEQ through the end of the third quarter 2022, a 5 |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| October 18, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| October 18, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE RVL Pharmaceuticals plc Announces Preliminary Third Quarter 2022 UPNEEQ? Net Product Sales - Expects third quarter 2022 preliminary UPNEEQ net product sales of approximately $10.0 million, representing an increase of 19% over the second quarter 2022 - - Third quarter 2022 net product sales growth contributed to approximately $24.4 million in sales for the nine mo |
|
| August 24, 2022 |
RVL PHARMACEUTICALS PLC 400 Crossing Boulevard Bridgewater, New Jersey 08807 RVL PHARMACEUTICALS PLC 400 Crossing Boulevard Bridgewater, New Jersey 08807 August 24, 2022 VIA EDGAR U. |
|
| August 19, 2022 |
As filed with the Securities and Exchange Commission on August 19, 2022. S-3 1 tm2223785d1s3.htm FORM S-3 As filed with the Securities and Exchange Commission on August 19, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland Not Applicable (State or other jurisdiction of i |
|
| August 19, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) RVL Pharmaceuticals plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity? Ordinary Shares, $0. |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| August 11, 2022 |
? Exhibit 10.4 SHARE SUBSCRIPTION AGREEMENT This Share Subscription Agreement (this ?Agreement?) is dated as of August 4, 2022 (the ?Effective Date?), by and between RVL Pharmaceuticals plc, a public limited company incorporated under the laws of Ireland (the ?Company?), and Brian Markison (the ?Purchaser?). WHEREAS, the Company, certain of its Subsidiaries and Athyrium Opportunities IV Co-Invest |
|
| August 11, 2022 |
Exhibit 10.1 ? FIRST AMENDMENT TO NOTE PURCHASE AGREEMENT THIS FIRST AMENDMENT TO NOTE PURCHASE AGREEMENT (this ?Agreement?) dated as of August 4, 2022 is entered into by and among OSMOTICA PHARMACEUTICAL CORP., a Delaware corporation (the ?Issuer?), the Guarantors party hereto, the Purchasers party hereto and ATHYRIUM OPPORTUNITIES IV ACQUISITION LP, as the Administrative Agent. All capitalized t |
|
| August 11, 2022 |
? ? Exhibit 10.3 SHARE SUBSCRIPTION AGREEMENT This Share Subscription Agreement (this ?Agreement?) is dated as of August 4, 2022 (the ?Effective Date?), by and between RVL Pharmaceuticals plc, a public limited company incorporated under the laws of Ireland (the ?Company?), and Athyrium Opportunities IV Co-Invest 2 LP, a Delaware limited partnership (the ?Purchaser?). WHEREAS, the Company, certain |
|
| August 11, 2022 |
? ? Exhibit 10.2 SHARE SUBSCRIPTION AGREEMENT This Share Subscription Agreement (this ?Agreement?) is dated as of August 4, 2022 (the ?Effective Date?), by and between RVL Pharmaceuticals plc, a public limited company incorporated under the laws of Ireland (the ?Company?), and Avista Healthcare Partners, L.P., a Bermuda limited partnership (the ?Purchaser?). WHEREAS, the Company, certain of its Su |
|
| August 11, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE RVL Pharmaceuticals plc Reports Second Quarter 2022 Financial Results; Provides Commercial Update - Second quarter 2022 UPNEEQ? net product sales of $8.4 million; 42% above first quarter - - Opportunity for cash runway to extend through 2023 following recently announced financings - - Expanded Board of Directors with the appointment of Alisa Lask, Aesthetic indus |
|
| August 11, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* RVL Pharmaceuticals plc (Name of Issuer) Ordinary Shares, nominal value $0.01 per share (Title of Class of Secu |
|
| August 11, 2022 |
? Exhibit 10.5 SHARE SUBSCRIPTION AGREEMENT This Share Subscription Agreement (this ?Agreement?) is dated as of August 4, 2022 (the ?Effective Date?), by and between RVL Pharmaceuticals plc, a public limited company incorporated under the laws of Ireland (the ?Company?), and James Schaub (the ?Purchaser?). WHEREAS, the Company, certain of its Subsidiaries and Athyrium Opportunities IV Co-Invest 2 |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 9, 2022 |
Exhibit 1 SHARE SUBSCRIPTION AGREEMENT This Share Subscription Agreement (this ?Agreement?) is dated as of August 4, 2022 (the ?Effective Date?), by and between RVL Pharmaceuticals plc, a public limited company incorporated under the laws of Ireland (the ?Company?), and Avista Healthcare Partners, L. |
|
| August 9, 2022 |
CUSIP No. G6S41R101 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 3)* RVL Pharmaceuticals plc (Name of Issuer) Ordinary Shares, nominal value $0.01 per share (Title of Class of Securities) G6S41R101 (CUSIP Number) Ben Silbert, Esq. 65 East 55th Street, 18th Floor New York, NY 10022 (212) 593-6900 (Name, |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| July 7, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE RVL Pharmaceuticals plc Announces Preliminary Second Quarter 2022 UPNEEQ? Net Product Sales Results - Expects second quarter 2022 preliminary UPNEEQ net product sales of approximately $8.4 million, representing an increase of 42% from the first quarter 2022 - - Second quarter 2022 net product sales growth contributes to approximately $14.4 million in the six mont |
|
| July 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2022 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commission |
|
| June 17, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commissio |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.?) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| May 12, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE RVL Pharmaceuticals plc Reports First Quarter 2022 Financial Results; Provides Commercial Update First quarter 2022 UPNEEQ net product sales of $5.9 million; 90% growth over fourth quarter 2021 First quarter 2022 total revenues of $21.4 million, inclusive of $15.5 million from Santen License Agreement, with related cash receipt in April 2022 Reaffirms fourth quar |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commission |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 25, 2022 |
proxy statement filed with the SEC on April 25, 2022 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.?) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.?) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 12, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.?) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2022 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commissio |
|
| April 6, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE RVL Pharmaceuticals plc Announces Preliminary First Quarter 2022 UPNEEQ? Net Product Sales Results - Expects first quarter 2022 preliminary UPNEEQ net product sales of approximately $5.9 million, representing an increase of 90% from the fourth quarter 2021 - - Reaffirms fourth quarter 2022 guidance of $20 to 25 million in UPNEEQ net product sales - - UPNEEQ selec |
|
| April 6, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2022 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commissio |
|
| April 4, 2022 |
Exhibit 10.1 FIRST Amendment to License Agreement This FIRST AMENDMENT TO LICENSE AGREEMENT (this ?First Amendment?) is made and entered into as of March 31, 2022 (the ?First Amendment Effective Date?) between RVL Pharmaceuticals, Inc., a Delaware corporation (?RVL?) and Santen Pharmaceutical Co. Ltd., a Japanese corporation (?Licensee?). RVL and Licensee may be referred to herein individually as |
|
| April 4, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| March 30, 2022 |
Exhibit 10.13 ? EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?), is entered into this 3rd day of December, 2015, by and between Vertical/Trigen Holdings, LLC, a Delaware limited liability company, and its successors and assigns (?Vertical/Trigen? or the ?Company?) and Brian A. Markison (the ?Executive?). WHEREAS, this Agreement is being entered into in connection with the enterin |
|
| March 30, 2022 |
RVL Pharmaceuticals plc Amended and Restated 2018 Incentive Plan Exhibit 10.11 ? RVL PHARMACEUTICALS PLC AMENDED AND RESTATED 2018 INCENTIVE PLAN 1.DEFINED TERMS The following terms, when used in the Plan (as defined below), have the meanings and are subject to the provisions set forth below: (a)?Accounting Rules?: Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor provision. (b)?Administrator?: The Compensation C |
|
| March 30, 2022 |
Exhibit 10.7 ? Name: [?] Number of Shares subject to the Stock Option: [?] Exercise Price Per Share: $[?] Date of Grant: [?] Vesting Commencement Date [?] ? ? RVL PHARMACEUTICALS PLC 2018 INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT ? This agreement (this ?Agreement?) evidences a stock option granted by the Company to the individual named above (the ?Optionee?), pursuant to and subject to t |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? FORM 10-K ? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? ? For the fiscal year ended December 31, 2021 ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to ? Commission file number 001-38709 ? RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) ? Ireland Not Applicable (State or other jurisdiction of (I. |
|
| March 30, 2022 |
? Exhibit 10.14 Brian Markison ? Dear Brian, The purpose of this letter is to effect an assignment of the Employment Agreement by and between the Company and you dated as of December 3, 2015 (the ?Employment Agreement?), effective as of July 29, 2021 (the ?Effective Date?) as describe more fully herein. Except as expressly provided for herein, the Employment Agreement shall remain in full force an |
|
| March 30, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| March 30, 2022 |
RVL Pharmaceuticals plc Amended and Restated 2018 Employee Share Purchase Plan Exhibit 10.8 ? RVL PHARMACEUTICALS PLC AMENDED AND RESTATED 2018 EMPLOYEE SHARE PURCHASE PLAN ? ? 1. Defined Terms Exhibit A, which is incorporated by reference, defines certain terms used in the Plan and sets forth certain operational rules related to those terms. 2. Purpose of Plan The Plan is intended to enable Eligible Employees to use payroll deductions to purchase Shares in offerings under t |
|
| March 30, 2022 |
Amended and Restated RVL Pharmaceuticals plc 2016 Equity Incentive Plan Exhibit 10.10 AMENDED AND RESTATED RVL PHARMACEUTICALS PLC 2016 EQUITY INCENTIVE PLAN AMENDED AND RESTATED EFFECTIVE AS OF AUGUST 14, 2018 ? ? ? TABLE OF CONTENTS Page No. ? SECTION 1. PURPOSE. 1 ? ? SECTION 2. ADMINISTRATION. 1 ? ? SECTION 3. ELIGIBILITY. 1 ? ? SECTION 4. SHARES SUBJECT TO PLAN. 2 ? ? ? a. Basic Limitation 2 ? b. Additional Shares 2 ? ? ? ? SECTION 5. AWARDS. 2 ? ? ? a. Types of |
|
| March 30, 2022 |
Subsidiaries of RVL Pharmaceuticals plc Exhibit 21.1 RVL Pharmaceuticals plc Subsidiary State or Other Jurisdiction of Organization RVL Holdings US LLC Delaware Osmotica Kereskedelmi es Szolgaltato Kft Hungary Osmotica Pharmaceutical Corp. Delaware RVL Pharmaceuticals, Inc. Delaware Osmotica Argentina, S.A. Argentina Valkyrie Group Holdings, Inc. Delaware RVL Pharmacy, LLC Delaware ? |
|
| March 30, 2022 |
Description of Registrant’s Securities Exhibit 4.4 ? DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of RVL Pharmaceuticals plc (the ?Company?, ?us?, ?we?, or ?our?) securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). The follo |
|
| March 30, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Preliminary First Quarter 2022 UPNEEQ? Revenue Estimate and Business Update Fourth quarter 2021 UPNEEQ product sales of $3.1 million, representing 39% growth over third quarter sales Fourth quarter and full year 2021 total revenues of $2.9 million and $17.5 million, resp |
|
| January 19, 2022 |
Exhibit 99.1 For Immediate Release Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol ?RVLP,? Plans to Launch UPNEEQ? into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance - Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 - - Fourth Quarter |
|
| January 19, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2022 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2022 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| January 18, 2022 |
Exhibit 3.1 to our Current Report on Form 8-K filed on January 18, 2022 Exhibit 3.1 A PUBLIC COMPANY LIMITED BY SHARES CONSTITUTION OF RVL PHARMACEUTICALS PUBLIC LIMITED COMPANY (adopted on 17 October 2018 and amended on 14 January 2022) COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF RVL PHARMACEUTICALS PUBLIC LIMITED COMPANY 1. The name of the Company is RVL Pharmaceuticals public limited company. 2. The Company is a public limited |
|
| December 8, 2021 |
DEF 14A 1 ny20001424x1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| December 7, 2021 |
OSMOTICA PHARMACEUTICALS PLC 400 Crossing Boulevard Bridgewater, New Jersey 08807 OSMOTICA PHARMACEUTICALS PLC 400 Crossing Boulevard Bridgewater, New Jersey 08807 December 7, 2021 VIA EDGAR U. |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2021 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-38709 (Commission File |
|
| November 16, 2021 |
As filed with the Securities and Exchange Commission on November 16, 2021 As filed with the Securities and Exchange Commission on November 16, 2021 REGISTRATION NO. |
|
| November 15, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Osmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business Update Third quarter Upneeq? product sales of $2.2 million, representing 47% growth over second quarter sales Expansion of Upneeq launch continues with introduction of Direct Dispense program in eyecare and formation of Aesthetics business unit Sale of legacy business and capita |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-38709 (Commission File |
|
| November 10, 2021 |
Amendment to Employment Agreement, by and between RVL and Brian Markison, dated November 5, 2021 EX-10.1 2 tm2132495d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 November 5, 2021 Brian Markison Dear Brian, The purpose of this letter is to amend the Employment Agreement by and between RVL Pharmaceuticals, Inc. (the “Company”) and you dated as of December 3, 2015, as amended effective July 29, 2021 (the “Employment Agreement”), effective as of November 5, 2021 (the “Effective Date”). Except as express |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-38709 (Commission File |
|
| November 3, 2021 |
OSMT / Osmotica Pharmaceuticals PLC / Altchem Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Osmotica Pharmaceuticals plc (Name of Issuer) Ordinary shares, nominal value $0.01 per share (Title of Class of Securities) G6S41R101 (CUSIP Number) David C. Camerini, Esq. c/o Fox Horan & Camerini LLP 885 Third Avenue, 17th Floor New York, NY 10022 (212) |
|
| October 27, 2021 |
As filed with the Securities and Exchange Commission on October 27, 2021. As filed with the Securities and Exchange Commission on October 27, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland Not Applicable (State or other jurisdiction of incorporation or organizatio |
|
| October 22, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Osmotica Pharmaceuticals plc (Name of Issuer) Ordinary Shares, nominal value $0.01 per share (Title of Class of Se |
|
| October 14, 2021 |
CUSIP No. G6S41R101 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Osmotica Pharmaceuticals plc (Name of Issuer) Ordinary Shares, nominal value $0.01 per share (Title of Class of Securities) G6S41R101 (CUSIP Number) Ben Silbert, Esq. 65 East 55th Street, 18th Floor New York, NY 10022 (212) 593-6900 (N |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2021 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-38709 (Commission File N |
|
| October 12, 2021 |
EX-1.1 2 tm2129380d4ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 14,000,000 Ordinary Shares Warrants to Purchase 14,000,000 Ordinary Shares Osmotica Pharmaceuticals plc UNDERWRITING AGREEMENT October 6, 2021 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 As Representative of the several Underwriters listed on Schedule A hereto Ladies and Gentlemen: Introductory. Osmotica Pharmaceuticals plc, a |
|
| October 12, 2021 |
Exhibit 4.1 ORDINARY SHARE PURCHASE WARRANT OSMOTICA PHARMACEUTICALS PLC Warrant Shares: Initial Exercise Date: October 12, 2021 THIS ORDINARY SHARE PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof |
|
| October 12, 2021 |
PART II INFORMATION NOT REQUIRED IN PROSPECTUS Exhibit 99.1 PART II INFORMATION NOT REQUIRED IN PROSPECTUS Item 14. Other Expenses of Issuance and Distribution. Set forth below is an estimate of the amount of fees and expenses to be incurred in connection with the issuance and distribution of the offered securities registered hereby, incurred in connection with the sale of the Company?s ordinary shares. All such amounts will be borne by Osmoti |
|
| October 8, 2021 |
14,000,000 Ordinary Shares Warrants to Purchase 14,000,000 Ordinary Shares TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ?Registration No. 333-236193? PROSPECTUS SUPPLEMENT (To Prospectus dated February 12, 2020) 14,000,000 Ordinary Shares Warrants to Purchase 14,000,000 Ordinary Shares We are offering 14,000,000 of our ordinary shares, and warrants to purchase 14,000,000 ordinary shares, in this offering. The public offering price for each ordinary share and acco |
|
| October 6, 2021 |
Exhibit 10.2 Execution Version SHARE SUBSCRIPTION AGREEMENT This Share Subscription Agreement (this ?Agreement?) is dated as of October 1, 2021 (the ?Effective Date?), between Osmotica Pharmaceuticals plc, a public limited company incorporated under the laws of Ireland (the ?Company?), and Athyrium Opportunities IV Acquisition 2 LP, a Delaware limited partnership (the ?Purchaser?). WHEREAS, the Co |
|
| October 6, 2021 |
SUBJECT TO COMPLETION, DATED OCTOBER 6, 2021 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| October 6, 2021 |
EX-10.1 2 tm2129380d2ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 THE NOTES ISSUED UNDER THIS NOTE PURCHASE AGREEMENT HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED OR REGISTERED PURSUANT TO ANY STATE SECURITIES LAW OR THE SECURITIES LAW OF ANY OTHER JURISDICTION AND NO NOTEHOLDER WILL HAVE THE RIGHT TO REQUIRE SUCH REGISTRATION O |
|
| October 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2021 Osmotica Pharmaceuticals plc (Exact Name of Registrant as Specified in Charter) Ireland (State or Other Jurisdiction of Incorporation) 001-38709 (Commission File Numbe |
|
| September 27, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2021 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-38709 (Commission F |
|
| September 27, 2021 |
Exhibit 99.1 Osmotica Pharmaceuticals plc Investor Presentation September 2021 1 Forward Looking Statements 2 RVL Eye Care $20M - $30M This presentation contains forward?looking statements. You should not rely upon forward?looking statements as predictions of future events. These forward-looking statements generally can be identified by the use of words such as ?anticipate,? ?expect,? ?plan,? ?cou |
|
| September 8, 2021 |
Exhibit 99.1 RISK FACTORS This Current Report on Form 8-K contains forward-looking information based on our current expectations. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Current Report on Form 8-K, including our consolidated financial statements and the related notes appearing elsewhere in this Current R |
|
| September 8, 2021 |
Up to $75,000,000 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-236193 PROSPECTUS SUPPLEMENT (To Prospectus dated February 12, 2020) Up to $75,000,000 Ordinary Shares We have entered into a sales agreement, or Sales Agreement, with Cantor Fitzgerald & Co., the sales agent, relating to the ordinary shares offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of t |
|
| September 8, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2021 OSMOTICA PHARMACEUTICALS PLC Commission File Number: 001-38709 Ireland (State or other jurisdiction of incorporation) Not Applicable (IRS Employer Identification No. |
|
| September 8, 2021 |
Exhibit 1.1 Osmotica Pharmaceuticals plc Ordinary Shares (par value $0.01 per share) Controlled Equity OfferingSM Sales Agreement September 8, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Osmotica Pharmaceuticals plc, an Irish public limited company (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?), as fol |
|
| September 8, 2021 |
Financial Statements and Exhibits, Other Events ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): September 8, 2021 ? Osmotica Pharmaceuticals plc (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? ? ? ? ? ? ? Ireland 001-38709 Not Applicable (State or Othe |
|
| September 8, 2021 |
EX-99.2 4 osmt-20210827xex99d2.htm EXHIBIT 99.2 Exhibit 99.2 ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The statements in the discussion and analysis regarding industry outlook, our expectations regarding the performance of our business and the forward-looking statements are subject to numerous risks and uncertainties, including, but not limited t |
|
| September 8, 2021 |
Report of Independent Registered Public Accounting Firm Table of Contents Exhibit 99.3 ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Report of Independent Registered Public Accounting Firm – Ernst & Young, LLP F-2 Consolidated Balance Sheets as of December 31, 2020 and 2019 F-3 Consolidated Statements of Operational and Comprehensive Loss for the Years Ended December 31, 2020 and 2019 F-4 Consolidated St |
|
| September 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2021 Osmotica Pharmaceuticals plc Commission File Number: 001-38709 Ireland (State or other jurisdiction of incorporation) Not Applicable (IRS Employer Identification No.) |
|
| September 2, 2021 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On August 27, 2021 (the ?Closing?), Osmotica Pharmaceuticals plc (the ?Company?) completed the previously announced sale of its legacy products business (the ?Legacy Business?) pursuant to the Purchase and Sale Agreement (the ?Purchase Agreement?) dated June 24, 2021 with Acella Holdings, LLC (the ?Purchaser?) and Alora |
|
| August 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Co |
|
| August 16, 2021 |
EX-99.1 2 tm2125225d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Osmotica Pharmaceuticals plc Reports Second Quarter 2021 Results and Provides Business Update Sale of legacy business to Alora Pharmaceuticals, LLC expected to close in third quarter 2021 Second quarter 2021 total Upneeq revenue of $11.5 million including a $10.0 million milestone payment from Santen Pharmaceutical Co. |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 30, 2021 |
Exhibit 10.1 EXECUTION VERSION CONTINGENT AMENDMENT AGREEMENT THIS CONTINGENT AMENDMENT AGREEMENT (this ?Agreement?) is entered into as of June 24, 2021, by and among, OSMOTICA PHARMACEUTICAL CORP., a Delaware corporation (?OPC?), VALKYRIE GROUP HOLDINGS, INC., a Delaware corporation (?Valkyrie? and together with OPC, the ?Borrowers?), OSMOTICA HOLDINGS US LLC, a Delaware limited liability company |
|
| June 30, 2021 |
Exhibit 2.1 Execution Version PURCHASE AND SALE AGREEMENT by and among THE SELLERS LISTED HEREIN, OSMOTICA PHARMACEUTICALS PLC, ACELLA HOLDINGS, LLC, and ALORA PHARMACEUTICALS, LLC Dated as of June 24, 2021 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 6 Section 1.1 Defined Terms 6 Section 1.2 Other Definitions 22 ARTICLE II THE SALE 24 Section 2.1 Sale and Purchase of Transferred Interests 24 Sect |
|
| June 30, 2021 |
Alora will acquire manufacturing operations in Marietta, Georgia in addition to legacy products Exhibit 99.1 Osmotica Pharmaceuticals plc Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals, LLC June 25, 2021 Osmotica will receive a $110 million upfront cash payment, with the potential to receive up to $60 million in additional milestone payments Alora will acquire manufacturing operations in Marietta, Georgia in addition to legac |
|
| June 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 Osmotica Pharmaceuticals plc Commission File Number: 001-38709 Ireland (State or other jurisdiction of incorporation) Not Applicable (IRS Employer Identification No.) 40 |
|
| June 21, 2021 |
Osmotica pharmaceuticals plc Amended and restated 2018 INCENTIVE PLAN EX-99.1 2 tm2120087d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Osmotica pharmaceuticals plc Amended and restated 2018 INCENTIVE PLAN 1. DEFINED TERMS The following terms, when used in the Plan (as defined below), have the meanings and are subject to the provisions set forth below: (a) “Accounting Rules”: Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Comm |
|
| June 1, 2021 |
Jefferies Healthcare Conference June 2021 Exhibit 99.1 Jefferies Healthcare Conference June 2021 Forward Looking Statements 1 This presentation contains forward - looking statements. You should not rely upon forward - looking statements as predictions of future events . These forward - looking statements generally can be identified by the use of words such as ?anticipate,? ?expect,? ?plan,? ?could, ? ?may,? ?will,? ?believe,? ?estimate,? |
|
| June 1, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| May 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| May 13, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Osmotica Pharmaceuticals plc Reports First Quarter 2021 Results and Provides Business Update First quarter 2021 total revenue of $23.9 million RVL Pharmaceuticals? Upneeq wins 2021 MedTech Breakthrough Award; gains recognition as outstanding health and medical technology product Upneeq sales trend higher, exhibiting strong sequential growth Strategic asset review |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Osmotica Pharmaceuticals plc (Name of Issuer) Ordinary Shares, nominal value $0.01 per share G6S41R101 (CUSIP Number) Orbit Co-Invest I, LLC c/o Paradox Capital Partners, LLC 1500 East Las Olas Blvd, Suite 200 Ft. Lauderdale, FL 33301 (Name, Address and T |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 26, 2021 |
proxy statement filed on April 26, 2021 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 30, 2021 |
Exhibit 4.2 ? Avista Healthcare Partners, LP 65 East 55th Street, 18th Floor New York, NY 10022 Attn: Ben Silbert ? Altchem Limited: ??????????, 6 CITY HOUSE 3032, ???????, ??????: Attn: Georgios Filippou ? Orbit Co-Invest I, LLC: c/o Paradox Capital Partners, LLC 1500 East Las Olas Blvd, 2nd Floor Ft. Lauderdale, Florida 33301 Attn: Harvey Kesner ? November 19, 2020 ? Ladies and Gentlemen: ? Refe |
|
| March 30, 2021 |
Subsidiaries of Osmotica Pharmaceuticals plc EX-21.1 5 osmt-20201231ex211ae34ba.htm EX-21.1 Exhibit 21.1 Osmotica Pharmaceuticals plc Subsidiary State or Other Jurisdiction of Organization Osmotica Holdings US LLC Delaware Osmotica Kereskedelmi es Szolgaltato Kft Hungary Osmotica Pharmaceutical Corp. Delaware RVL Pharmaceuticals, Inc. Delaware Osmotica Argentina, S.A. Argentina Valkyrie Group Holdings, Inc. Delaware Vertical/Trigen Holdings, |
|
| March 30, 2021 |
EX-99.1 2 tm2111289d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Osmotica Pharmaceuticals plc Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update Fourth quarter and full year 2020 total revenue of $34.5 million and $177.9 million, respectively Received FDA approval and subsequently introduced Upneeq® (oxymetazoline hydrochloride ophthalmic solution, 0.1%), |
|
| March 30, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Com |
|
| March 30, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? FORM 10-K ? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? ? For the fiscal year ended December 31, 2020 ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to ? Commission file number 001-38709 ? Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) ? Ireland Not Applicable (State or other jurisdiction of (I. |
|
| March 30, 2021 |
Exhibit 10.25 ? CONFORMED COPY First Amendment dated as of November 10, 2016; Second Amendment dated as of April 28, 2017 and Third Amendment dated as of December 21, 2017 Second Amendment dated as of April 28, 2017; Third Amendment dated as of December 21, 2017; Limited Consent dated as of May 21, 2020; and Fourth Amendment dated as of December 12, 2020 ? CREDIT AGREEMENT Dated as of February 3, |
|
| March 30, 2021 |
Description of Osmotica Securities Exhibit 4.4 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of Osmotica Pharmaceuticals plc (the ?Company?, ?us?, ?we?, or ?our?) securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). The fo |
|
| March 9, 2021 |
Corporate Presentation Barclays Global Healthcare Conference March 2021 Exhibit 99.1 Corporate Presentation Barclays Global Healthcare Conference March 2021 Forward Looking Statements This presentation contains forward - looking statements. You should not rely upon forward - looking statements as predictions of future events . These forward - looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “wil |
|
| March 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2021 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Comm |
|
| January 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2021 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (C |
|
| December 29, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Osmotica Pharmaceuticals plc Receives Complete Response Letter from U.S. Food and Drug Administration for Arbaclofen Extended Release Tablets Bridgewater, NJ, December 29, 2020 – Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) |
|
| December 29, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2020 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) ( |
|
| December 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2020 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) ( |
|
| December 4, 2020 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-236193 PROSPECTUS SUPPLEMENT (To Prospectus dated February 12, 2020) 45,368,325 Ordinary Shares This prospectus supplement supplements, updates and amends the selling shareholder information contained in the prospectus dated February 12, 2020, relating to the resale by selling shareholders of our ordinary shares that may be offered and sold fro |
|
| November 27, 2020 |
OSMT / Osmotica Pharmaceuticals plc / Orbit Co-Invest I LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Osmotica Pharmaceuticals plc (Name of Issuer) Ordinary Shares, nominal value $0.01 per share G6S41R101 (CUSIP Number) Orbit Co-Invest I, LLC c/o Paradox Capital Partners, LLC 1500 East Las Olas Blvd, 2nd Floor Ft. Lauderdale, FL 33304 (Name, Address and Te |
|
| November 23, 2020 |
Exhibit 3 Avista Healthcare Partners, LP 65 East 55th Street, 18th Floor New York, NY 10022 Attn: Ben Silbert Altchem Limited: Καραϊσκάκη, 6 CITY HOUSE 3032, Λεμεσός, Κύπρος: Attn: Georgios Filippou Orbit Co-Invest I, LLC: c/o Paradox Capital Partners, LLC 1500 East Las Olas Blvd, 2nd Floor Ft. |
|
| November 23, 2020 |
CUSIP No. G6S41R101 Page 1 of 10 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 1)* Osmotica Pharmaceuticals plc (Name of Issuer) Ordinary Shares, nominal value $0.01 per share (Title of Class of Securities) G6S41R101 (CUSIP Number) Ben Silbert, Esq. 65 East 55th Street, 18th Floor New York, NY 10022 (212 |
|
| November 23, 2020 |
Exhibit 4 Execution Version LETTER AGREEMENT This LETTER AGREEMENT (this “Agreement”) is entered into on November 19, 2020, by and among Avista Capital Partners III GP, L. |
|
| November 23, 2020 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing on behalf of each of them of the Statement on Schedule 13D with respect to the ordinary shares, $0. |
|
| November 10, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38709 |
|
| November 10, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Osmotica Pharmaceuticals plc Reports Third Quarter 2020 Results and Provides Business Updates Third quarter 2020 total revenue of $57.2 million Received U.S Food and Drug Administration (?FDA?) approval for Upneeq? (oxymetazoline hydrochloride ophthalmic solution), 0.1% for acquired blepharoptosis (ptosis or droopy eyelid) in adults Launched Upneeq from new opera |
|
| November 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) ( |
|
| September 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A (Amendment No. |
|
| September 4, 2020 |
Osmotica Pharmaceuticals plc HAS REQUESTED CONFIDENTIAL TREATMENT OF THE REDACTED PORTIONS OF THIS LETTER, WHICH WERE REPLACED WITH THE FOLLOWING PLACEHOLDER “[***]” IN THE LETTER FILED VIA EDGAR UNDER RULE 83 OF THE SECURITIES AND EXCHANGE COMMISSION’S RULES OF PRACTICE. |
|
| August 11, 2020 |
Exhibit 10.3 Name: [•] Target Number of PSUs subject to Award: [•] Date of Grant: [•] OSMOTICA PHARMACEUTICALS PLC 2018 INCENTIVE PLAN PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT (EMPLOYEE) This agreement (including any appendix, exhibit and/or addendum hereto, collectively, this “Agreement”) evidences an award (the “Award”) of performance-based restricted stock units granted by the Co |
|
| August 11, 2020 |
Exhibit 10.2 Name: [•] Number of Restricted Stock Units subject to Award: [•] Date of Grant: [•] OSMOTICA PHARMACEUTICALS PLC 2018 INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (EMPLOYEE) This agreement (this “Agreement”) evidences an award (the “Award”) of restricted stock units granted by the Company to the individual named above (the “Grantee”), pursuant to and subject to the terms of th |
|
| August 11, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38709 Osmo |
|
| August 11, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Osmotica Pharmaceuticals plc Reports Second Quarter 2020 Results and Provides Business Updates Second quarter 2020 total revenue of $37.5 million Received U.S Food and Drug Administration (“FDA”) approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for acquired blepharoptosis (ptosis or droopy eyelid) in adults Entered into exclusive licen |
|
| August 11, 2020 |
UPNEEQ™ US Commercial Update August 2020 Exhibit 99.2 UPNEEQ™ US Commercial Update August 2020 1 © 2020 Osmotica Pharmaceuticals plc. Safe Harbor This presentation contains forward - looking statements. You should not rely upon forward - looking statements as predictions of future events. All statements other than statements of historical facts contained in this presentation, including information concerning the ti ming of clinical and c |
|
| August 11, 2020 |
Exhibit 10.4 Name: [•] Number of Restricted Stock Units subject to Award: [•] Date of Grant: [•] OSMOTICA PHARMACEUTICALS PLC 2018 INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (NON-EMPLOYEE DIRECTOR) This agreement (this “Agreement”) evidences an award (the “Award”) of restricted stock units granted by the Company to the individual named above (the “Grantee”), pursuant to and subject to th |
|
| August 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Co |
|
| August 11, 2020 |
Osmotica Pharmaceuticals plc Amended and Restated 2018 Employee Share Purchase Plan Exhibit 10.1 OSMOTICA PHARMACEUTICALS PLC AMENDED AND RESTATED 2018 EMPLOYEE SHARE PURCHASE PLAN 1. Defined Terms Exhibit A, which is incorporated by reference, defines certain terms used in the Plan and sets forth certain operational rules related to those terms. 2. Purpose of Plan The Plan is intended to enable Eligible Employees to use payroll deductions to purchase Shares in offerings under th |
|
| July 31, 2020 |
Exhibit 99.1 Execution Version CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. LICENSE AGREEMENT between RVL Pharmaceuticals, Inc. and SANTEN PHARMACEUTICAL CO. LTD. Dated as of July 28, 2 |
|
| July 31, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2020 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Comm |
|
| July 15, 2020 |
5,000,000 Shares Ordinary Shares Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| July 15, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2020 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Comm |
|
| July 15, 2020 |
PART II INFORMATION NOT REQUIRED IN PROSPECTUS EX-99.1 4 tm2024554d4ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PART II INFORMATION NOT REQUIRED IN PROSPECTUS Item 14. Other Expenses of Issuance and Distribution. Set forth below is an estimate (except in the case of the registration fee and FINRA fee) of the amount of fees and expenses to be incurred in connection with the issuance and distribution of the offered securities registered hereby, incurre |
|
| July 15, 2020 |
Exhibit 1.1 EXECUTION VERSION 5,000,000 Osmotica Pharmaceuticals plc UNDERWRITING AGREEMENT July 13, 2020 Credit Suisse Securities (USA) LLC Eleven Madison Avenue, New York, NY 10010-3629 As Representative of the several Underwriters Ladies and Gentlemen: Introductory. Osmotica Pharmaceuticals plc, an Irish public limited company (the “Company”), proposes to issue and allot to the several underwri |
|
| July 14, 2020 |
SUBJECT TO COMPLETION, DATED JULY 13, 2020 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| July 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2020 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Comm |
|
| July 13, 2020 |
Osmotica Announces Proposed Public Offering of Ordinary Shares EX-99.1 2 tm2024554d3ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Osmotica Announces Proposed Public Offering of Ordinary Shares BRIDGEWATER, N.J., July 13, 2020 (GLOBE NEWSWIRE) – Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the commencement of a proposed public offering of 5,000,000 ordinary shares. All of the sh |
|
| May 27, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2020 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| May 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| May 12, 2020 |
EX-99.1 2 tm2019386d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Osmotica Pharmaceuticals plc Reports First Quarter 2020 Results and Provides Business Updates First quarter 2020 total revenue of $48.6 million On track to achieve major 2020 milestones Bridgewater, NJ, May 12, 2020 – Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharm |
|
| May 12, 2020 |
10-Q 1 osmt-20200331x10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Co |
|
| April 20, 2020 |
our proxy statement filed on April 20, 2020 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 8, 2020 |
OSMT / Osmotica Pharmaceuticals plc PRE 14A - - PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2020 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Com |
|
| March 19, 2020 |
Subsidiaries of Osmotica Pharmaceuticals plc EX-21.1 6 osmt-20191231ex2110163ba.htm EX-21.1 Exhibit 21.1 Osmotica Pharmaceuticals plc Subsidiary State or Other Jurisdiction of Organization Osmotica Holdings S.C.Sp. Luxembourg Osmotica Holdings US LLC Delaware Osmotica Holdings Corp LTD Cyprus Osmotica Kereskedelmi es Szolgaltato Kft Hungary Osmotica Pharmaceutical Corp. Delaware RevitaLid, Inc. Delaware Osmotica Argentina, S.A. Argentina Orb |
|
| March 19, 2020 |
Exhibit 10.36 INITIAL RETAINER AGREEMENT (In Lieu of Equity Awards) THIS INITIAL RETAINER AGREEMENT (this “Agreement”) is entered into as of [] by and between Osmotica Pharmaceuticals plc (the “Company”), and [] (the “Director”) and shall be effective as of the date hereof (the “Effective Date”). 1. Initial Retainer. If the Director has served continuously as a member of the board of directors of |
|
| March 19, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38709 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland Not Applicable (State or other jurisdiction of (I. |
|
| March 19, 2020 |
EX-10.37 5 osmt-20191231ex10379f85d.htm EX-10.37 Exhibit 10.37 ADDITIONAL ANNUAL RETAINER AGREEMENT (In Lieu of Equity Awards) THIS ADDITIONAL ANNUAL RETAINER AGREEMENT (this “Agreement”) is entered into as of [] by and between Osmotica Pharmaceuticals plc (the “Company”), and [] (the “Director”) and shall be effective as of the date hereof (the “Effective Date”). 1. Additional Annual Retainer. If |
|
| March 19, 2020 |
Description of Osmotica Securities Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of Osmotica Pharmaceuticals plc (the “Company”, “us”, “we”, or “our”) securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The fo |
|
| March 19, 2020 |
Exhibit 10.35 EMPLOYMENT AGREEMENT This Employment Agreement (this "Agreement"), dated December 16, 2013, is entered into by and between Ve1iical/Trigen Opco, LLC (the "Company"), which is a wholly-owned subsidiary of Verticalffrigen Holdings, LLC ("Holdings"), and Christopher Klein (the "Executive"). WHEREAS, the Company desires that Executive become employed by, and Executive desires to be emplo |
|
| March 18, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Osmotica Pharmaceuticals plc Reports Fourth Quarter and Full Year 2019 Results and Provides Business Updates Fourth quarter and full year 2019 total revenue of $59.9 million and $240.0 million, respectively New Drug Application accepted by FDA for RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for acquired blepharoptosis, or droopy eyelid; user |
|
| March 18, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2020 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Com |
|
| March 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2020 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Comm |
|
| February 10, 2020 |
OSMT / Osmotica Pharmaceuticals plc CORRESP - - CORRESP 1 filename1.htm OSMOTICA PHARMACEUTICALS PLC 400 Crossing Boulevard Bridgewater, New Jersey 08807 February 10, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Osmotica Pharmaceuticals plc Registration Statement on Form S-3 (File No. 333-236193) Request for Acceleration Ladies and Gentlemen: Pursuant to Rul |
|
| January 31, 2020 |
OSMT / Osmotica Pharmaceuticals plc S-3 - - S-3 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on January 31, 2020. |
|
| January 31, 2020 |
Exhibit 4.7 OSMOTICA PHARMACEUTICALS PLC And [ ] as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 Definitions. 1 1.2 Other Definitions 5 1.3 Incorporation by Reference of Trust Indenture Act 5 1.4 Rules of Construction Unless the context otherwise requires: 6 ARTICLE 2 THE SECURITIES 6 2.1 Issuable in Series 6 2.2 Establishment of Term |
|
| January 23, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 23, 2020 |
Exhibit 2 Execution Version SHAREHOLDERS AGREEMENT DATED AS OF OCTOBER 17, 2018 AMONG OSMOTICA PHARMACEUTICALS PLC ACP HOLDCO (OFFSHORE), L. |
|
| January 23, 2020 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing on behalf of each of them of the Statement on Schedule 13D with respect to the ordinary shares, $0. |
|
| January 22, 2020 |
OSMT / Osmotica Pharmaceuticals plc / Altchem Ltd - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Osmotica Pharmaceuticals plc (Name of Issuer) Ordinary shares, nominal value $0.01 per share (Title of Class of Securities) G6S41R101 (CUSIP Number) David C. Camerini, Esq. c/o Fox Horan & Camerini LLP 885 Third Avenue, 17th Floor New York, NY 10022 (212) |
|
| January 10, 2020 |
6,000,000 Shares Osmotica Pharmaceuticals plc Ordinary Shares Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. |
|
| January 6, 2020 |
OSMT / Osmotica Pharmaceuticals plc S-1/A - - S-1/A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on January 6, 2020. |
|
| January 6, 2020 |
Form of Underwriting Agreement Exhibit 1.1 [ · ] Osmotica Pharmaceuticals plc UNDERWRITING AGREEMENT January [ · ], 2020 JEFFERIES LLC SVB Leerink LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, MA 02110 Ladies and Gentlemen: Introductory. Osmotica Pharmaceuticals plc, an Irish public limited company (the |
|
| January 6, 2020 |
OSMT / Osmotica Pharmaceuticals plc CORRESP - - VIA EDGAR January 6, 2020 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Osmotica Pharmaceuticals plc (the “Company”) Registration Statement on Form S-1 (File No. 333-235661) Ladies and Gentlemen: As representatives of the several underwriters of the Company’s proposed public offering of ordinary shares, we hereby join the Company’s request that the effective date |
|
| December 20, 2019 |
EX-99.1 3 osmt-20191220ex991b49ccd.htm EX-99.1 Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The statements in the discussion and analysis regarding industry outlook, our expectations regarding the performance of our business and the forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the ri |
|
| December 20, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2019 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) ( |
|
| December 20, 2019 |
Subsidiaries of Osmotica Pharmaceuticals plc QuickLinks - Click here to rapidly navigate through this document Exhibit 21.1 Osmotica Pharmaceuticals plc Subsidiary State or Other Jurisdiction of Organization Osmotica Holdings S.C.Sp. Luxembourg Osmotica Holdings US LLC Delaware Osmotica Holdings Corp LTD Cyprus Osmotica Kereskedelmi es Szolgaltato Kft Hungary Osmotica Pharmaceutical Corp. Delaware RevitaLid, Inc. Delaware Osmotica Argentina, |
|
| December 20, 2019 |
Powers of Attorney (included on the signature page) Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on December 20, 2019. |
|
| November 14, 2019 |
EX-99.1 2 a19-229011ex99d1.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Osmotica Pharmaceuticals plc Reports Third Quarter 2019 Results Third quarter 2019 total revenue of $65.5 million Submitted NDA for RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for acquired blepharoptosis, or droopy eyelid, to FDA Bridgewater, NJ, November 14, 2019 — Osmotica Pharmaceuticals plc (Nasdaq: |
|
| November 14, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38709 |
|
| November 14, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2019 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) ( |
|
| September 27, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2019 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) |
|
| September 27, 2019 |
Osmotica Pharmaceuticals plc Appoints Industry Executive Michael J. DeBiasi to Board of Directors Exhibit 99.1 FOR IMMEDIATE RELEASE Osmotica Pharmaceuticals plc Appoints Industry Executive Michael J. DeBiasi to Board of Directors Bridgewater, NJ, September 27, 2019 — Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced the appointment of Michael J. DeBiasi to the Company’s Board of Directors, effective as of O |
|
| September 4, 2019 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2019 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Co |
|
| August 12, 2019 |
OSMT / Osmotica Pharmaceuticals plc DEF 14A - - DEF 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 8, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2019 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of incorporation) (Com |
|
| August 8, 2019 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Osmotica Pharmaceuticals plc Reports Second Quarter 2019 Results Second quarter 2019 total revenue of $57.5 million On track to submit NDA for RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for acquired blepharoptosis, or droopy eyelid, by end of Q3 2019 Bridgewater, NJ, August 8, 2019 — Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) |
